Argenica Therapeutics Ltd(AGN.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

AGN.AU Argenica Therapeutics Ltd

Trading 12-17 11:34:07 AEDT

0.28

+0.02

+7.69%

High0.29	Low0.28	Vol8.48K
Open0.29	D1 Closing0.26	Amplitude3.85%
Mkt Cap35.97M	Tradable Cap25.63M	Total Shares128.46M
T/O2.42K	T/O Rate0.01%	Tradable Shares91.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGN.AU","market":"AU","secType":"STK","nameCN":"Argenica Therapeutics Ltd","latestPrice":0.28,"timestamp":1765928689193,"preClose":0.26,"halted":0,"volume":8476,"delay":0,"nameEN":"Argenica Therapeutics Ltd","floatShares":91529130,"shares":128456712,"eps":-0.056226,"marketStatus":"Trading","change":0.02,"latestTime":"12-17 11:34:07 AEDT","open":0.29,"high":0.29,"low":0.28,"amount":2424,"amplitude":0.038462,"askPrice":0.275,"askSize":13696,"bidPrice":0.27,"bidSize":3800,"shortable":3,"etf":0,"ttmEps":-0.056226,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765947600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.26,"openAndCloseTimeList":[[1765926000000,1765947600000]],"volumeRatio":0.128988,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/AGN.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2590192524","title":"Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2590192524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590192524?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:03","pubTimestamp":1765512212,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics'  artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.Argenica Therapeutics' shares fell past 3% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK7096","BK4007","BK4539","AGN.AU"],"gpt_icon":0},{"id":"2588507442","title":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588507442","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588507442?lang=en_us&edition=fundamental","pubTime":"2025-12-04 11:05","pubTimestamp":1764817526,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition** Shares of Australia's Argenica Therapeutics AGN.AX surge as much as 34.1% to A$0.295, their highest since November 3** Biotech f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2582496253","title":"Argenica Therapeutics Ltd-Non-Executive Director Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582496253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582496253?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:49","pubTimestamp":1762926574,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE4DZW6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2575334275","title":"New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2575334275","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575334275?lang=en_us&edition=fundamental","pubTime":"2025-10-15 11:00","pubTimestamp":1760497239,"startTime":"0","endTime":"0","summary":"Latest results from Argenica Therapeutics' (ASX:AGN) second phase trial of neuroprotective drug candidate ARG-007 in acute ischemic stroke showed \"encouraging\" signs of functional improvement across c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGN.AU","BK4007","LENZ","BK4139","BK7096","BK4539"],"gpt_icon":0},{"id":"2564299713","title":"Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564299713","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564299713?lang=en_us&edition=fundamental","pubTime":"2025-09-04 15:25","pubTimestamp":1756970704,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  phase 2 trial of ARG-007 showed strong safety and a meaningful efficacy signal in a key high-risk subgroup, materially de-risking the program and supporting partnering potential, Euroz Hartleys said in a note on Thursday.The company shared phase 2 results showing ARG-007 was safe but did not reduce infarct volume overall in acute ischemic stroke patients.It further added that, in a pre-specified subgroup with slow collateral blood flow, which includes about 30% of participants and represents a third of large vessel occlusion strokes, ARG-007 reduced brain injury by 15%.The firm shared that despite missing broader efficacy goals, ARG-007 showed a meaningful effect in a pre-specified high-risk subgroup and has a strong safety profile supporting a planned phase 2 trial before moving to phase 3.The firm has issued a speculative buy recommendation for Argenica Therapeutics with a per-share target price of AU$1.40, which is currently under review.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","BK7096","AGN.AU","LENZ","BK4539"],"gpt_icon":0},{"id":"2564868323","title":"BRIEF-Argenica Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2564868323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564868323?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681355,"startTime":"0","endTime":"0","summary":"BRIEF-Argenica Therapeutics Seeks Trading Halt Sept 1 (Reuters) - Argenica Therapeutics Ltd AGN.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE 2 ARG-007  STROKE TRIAL RESULTSFurther company coverage: AGN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2564683288","title":"Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007  Stroke Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2564683288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564683288?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681334,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2562608845","title":"Argenica Therapeutics Ltd -  FY Loss Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562608845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562608845?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2562088437","title":"Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562088437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562088437?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2559632936","title":"Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2559632936","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559632936?lang=en_us&edition=fundamental","pubTime":"2025-08-14 11:50","pubTimestamp":1755143439,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  received a full clinical hold letter from the US Food and Drug Administration  on the reasons for the imposed clinical hold and the information required to lift the hold regarding its investigational new drug application, enable clinical trials of the ARG-007 drug candidate in acute ischaemic stroke in the US, according to a Thursday Australian bourse filing.The regulator requested additional information to ensure that the proposed trial dosing for a US trial can be achieved safely in humans, and the firm plans to use its phase two acute ischaemic stroke trial safety data, which will be available in September, as part of its response.The FDA also requested Argenica to conduct three additional in vitro cell culture studies with clinical research organizations to address identified gaps in data. It also asked the firm to include more detail on the phase one data in the investigational brochure.The firm's shares fell 1% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","AGN.AU","BK4539","BK7096"],"gpt_icon":0},{"id":"2557317283","title":"Argenica Therapeutics Ltd-Argenica Appoints Vice President of Regulatory Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2557317283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557317283?lang=en_us&edition=fundamental","pubTime":"2025-08-06 06:15","pubTimestamp":1754432155,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nTUE3KMQBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2553291383","title":"A 5% Reduction in Brain Cell Injury Volume Significant for Argenica's Acute Ischemic Stroke Treatment Candidate, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2553291383","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553291383?lang=en_us&edition=fundamental","pubTime":"2025-07-23 14:13","pubTimestamp":1753251195,"startTime":"0","endTime":"0","summary":"A 5% to 10% reduction in the volume of brain cell injury would be considered clinically and commercially meaningful for Argenica Therapeutics'  lead treatment candidate, ARG-007, which is being developed as a neuroprotective therapy for acute ischemic stroke, Euroz Hartleys said in a note on Wednesday.It is currently in a phase two trial in acute ischemic stroke patients with large vessel occlusion who have undergone endovascular thrombectomy. Top-line results are expected in the third quarter.The firm added that the literature suggests that even a 1.6% reduction could be considered clinically meaningful.Euroz Hartleys has a speculative buy rating for the firm with a price target of AU$1.40.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2550351685","title":"Cleansing Notice-AGN.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550351685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550351685?lang=en_us&edition=fundamental","pubTime":"2025-07-09 15:05","pubTimestamp":1752044703,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX6V850R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX1L6FMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2550858316","title":"Application for quotation of securities - AGN-AGN.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550858316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550858316?lang=en_us&edition=fundamental","pubTime":"2025-07-09 15:02","pubTimestamp":1752044526,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX1vd384","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX7HvkwZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2544197161","title":"BUZZ-Australia's Argenica Therapeutics rises on funding from federal government","url":"https://stock-news.laohu8.com/highlight/detail?id=2544197161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544197161?lang=en_us&edition=fundamental","pubTime":"2025-06-20 08:44","pubTimestamp":1750380272,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics rises on funding from federal government** Shares of Argenica Therapeutics AGN.AX rise as much as 2.1% to A$0.735 to hit highest level since June 11; last up 0.7%** Biotechnology co gets federal government funding up to A$1.5 million  to advance later stage clinical trial of ARG-007 being developed to treat stroke patients** Stock up ~15% this year, including the day's move","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nL6N3SN01F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.04},{"period":"3month","weight":-0.1875},{"period":"6month","weight":-0.6389},{"period":"1year","weight":-0.6},{"period":"ytd","weight":-0.5873}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0834},{"period":"1year","weight":0.2304},{"period":"ytd","weight":0.2344}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000888},{"month":2,"riseRate":0.5,"avgChangeRate":0.022009},{"month":3,"riseRate":0,"avgChangeRate":-0.126601},{"month":4,"riseRate":0.75,"avgChangeRate":0.134124},{"month":5,"riseRate":0.25,"avgChangeRate":-0.069298},{"month":6,"riseRate":0.6,"avgChangeRate":-0.00748},{"month":7,"riseRate":0.6,"avgChangeRate":0.052661},{"month":8,"riseRate":0.2,"avgChangeRate":-0.033499},{"month":9,"riseRate":0.6,"avgChangeRate":0.005063},{"month":10,"riseRate":0.6,"avgChangeRate":0.177186},{"month":11,"riseRate":0.6,"avgChangeRate":0.089526},{"month":12,"riseRate":0.5,"avgChangeRate":0.026728}],"exchange":"ASX","name":"Argenica Therapeutics Ltd","nameEN":"Argenica Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Argenica Therapeutics Ltd(AGN.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Argenica Therapeutics Ltd(AGN.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Argenica Therapeutics Ltd,AGN.AU,Argenica Therapeutics Ltd股票,Argenica Therapeutics Ltd股票老虎,Argenica Therapeutics Ltd股票老虎国际,Argenica Therapeutics Ltd行情,Argenica Therapeutics Ltd股票行情,Argenica Therapeutics Ltd股价,Argenica Therapeutics Ltd股市,Argenica Therapeutics Ltd股票价格,Argenica Therapeutics Ltd股票交易,Argenica Therapeutics Ltd股票购买,Argenica Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Argenica Therapeutics Ltd(AGN.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Argenica Therapeutics Ltd(AGN.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction